Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The results were heterogeneous: some trials, such as AMPLITUDE-O and SELECT, demonstrated significant reductions in HF-related endpoints, whereas others, like LEADER, showed only non-significant favourable trends
The drug companies dont like that, he said
More at Molecule of the Month: GLP-1 Receptor Agonists I am reposting this topic for wider visibility
Paulus WJ, Tschpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
US$ 25.81
US$ 26.17
US$ 21.16
US$ 23.76
US$ 22.58
US$ 27.33
US$ 22.07
US$ 27.22
US$ 26.76
